Ernexa Therapeutics Inc. Long-term Line of Credit
Ernexa Therapeutics Inc. (ERNA) had Long-term Line of Credit of $4.10 million as of 2024-08-05, per its 10-K filed 2025-03-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LineOfCredit · last filed 2025-03-12
- 2024-08-05: Long-term Line of Credit $4.10M.
- 2022-10-31: Long-term Line of Credit $4.10M.
- 2022-10-18: Long-term Line of Credit $4.10M.
- 2016-12-31: Long-term Line of Credit $97.00K.
| Period end | Long-term Line of Credit |
|---|---|
| 2024-08-05 | $4.10M 10-K · filed 2025-03-12 |
| 2022-10-31 | $4.10M 10-K · filed 2025-03-12 |
| 2022-10-18 | $4.10M 10-K · filed 2023-03-20 |
| 2016-12-31 | $97.00K 10-K · filed 2017-03-09 |
| 2016-09-30 | $139.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $110.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $103.00K 10-Q · filed 2016-05-09 |
| 2014-12-31 | $5.32M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |